Immunogenicity and safety of seasonal influenza vaccine co-administered with other vaccines: a systematic review and meta-analysis.
10 affiliations
- 1Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Centre (UGMLC), Philipps University Marburg, German Centre for Lung Research (DZL), Marburg, Germany.
- 2Internal Medicine Department, Aigli Medical Clinic, Athens, Greece.
- 3Centre for Research and Education in Public Health (CEPHRE), Academy of Athens, Athens, Greece.
- 4Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
- 5Center for Anesthesia Research Excellence (CARE), Beth Israel Deaconess Medical Center, Boston, MA, USA.
- 6Center for Synthetic Microbiology (SYNMIKRO), Philipps University Marburg, Marburg, Germany.
- 7Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Centre (UGMLC), Philipps University Marburg, German Centre for Lung Research (DZL), Marburg, Germany. [email protected].
- 8Centre for Research and Education in Public Health (CEPHRE), Academy of Athens, Athens, Greece. [email protected].
- 9Institute of Clinical Chemistry and Laboratory Medicine, Institute of Virology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. [email protected].
- 10Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA. [email protected].
Abstract
Seasonal influenza remains a leading cause of global morbidity and mortality, highlighting the need for vaccination strategies that improve coverage and streamline vaccine delivery. In this systematic review and meta-analysis, we searched PubMed, Embase, Web of Science, Scopus, and the Cochrane Central Register of Controlled Trials for randomised controlled trials (RCTs), cohort, case-control, and cross-sectional studies, evaluating immunogenicity and safety of same-day co-administration of influenza vaccines with COVID-19 or other vaccines, compared with non-concomitant administration. Comparators included sequential administration, single vaccine administration or placebo-controlled delayed vaccination. Risk of bias was evaluated using the Cochrane Risk-of-Bias tool for Randomized Trials and Risk of Bias In Non-randomized Studies of Interventions; certainty of evidence was evaluated using Grading of Recommendations, Assessment, Development and Evaluation. Immunogenicity was assessed using geometric mean fold rise (GMFR) in antibody titres and seroprotection rate. Safety was assessed by adverse event (AE) incidence. 52 eligible studies were included. Influenza immunogenicity was comparable between the co-administration and non-concomitant comparator group across all strains (H1N1 GMFR ratio of means (ROM): 1.02 [95% CI: 0.95-1.10]; H3N2, 1.05 [95% CI: 0.97-1.13]; B strain, 1.01 [95% CI: 0.97-1.05]). Pooled risk ratio (RR) for seroprotection was 1.00 for all three strains with 95% CIs ranging from 0.99-1.01. GMFR for COVID-19 vaccines was modestly reduced under co-administration (ROM 0.84 [95% CI: 0.74-0.95]; p = 0.006). Serious AEs were more frequent in the co-administration group compared to the non-concomitant group (RR 1.41 [95% CI: 1.07-1.86]; p = 0.014; absolute risk difference: 1.56 percentage points). Overall, co-administration preserves influenza immunogenicity but modestly reduces COVID-19 vaccine GMFR. Although safety findings warrant cautious interpretation, the low absolute risk difference supports its feasibility as a strategy to streamline vaccination schedules and improve uptake.
Related
- Comparative immunogenicity of several inactivated influenza vaccines among healthcare workers in Hong Kong
- Comparative immunogenicity and relative vaccine efficacy of recombinant and cell culture-based influenza vaccines: Results from a randomized trial of adults in the United States, 2024-2025
- Humoral Immunogenicity of mRNA-1010, an mRNA-based Seasonal Influenza Vaccine, in Adults ≥50 Years.
- Epitope-guided optimization improves the protective efficacy of NA-based mRNA vaccines against seasonal influenza A(H3N2) virus.
- Efficacy, Immunogenicity, Safety, and Evidence Independence of CYD-TDV and TAK-003 Dengue Vaccines in Children and Adolescents: A Systematic Review and Meta-Analysis.
BibTeX
@article{asri2026immunogenicity,
title = {{Immunogenicity and safety of seasonal influenza vaccine co-administered with other vaccines: a systematic review and meta-analysis.}},
author = {Samuel Asri and Paraskevi C Fragkou and Elena Ahrens and Svenja S Hartmann and Clemens Thölken and Chrysanthi Skevaki},
journal = {NPJ vaccines},
year = {2026},
month = sep,
doi = {10.1038/s41541-026-01548-z},
url = {https://europepmc.org/article/MED/42972001},
note = {CC BY},
}
RIS
TY - JOUR
TI - Immunogenicity and safety of seasonal influenza vaccine co-administered with other vaccines: a systematic review and meta-analysis.
AU - Samuel Asri
AU - Paraskevi C Fragkou
AU - Elena Ahrens
AU - Svenja S Hartmann
AU - Clemens Thölken
AU - Chrysanthi Skevaki
PY - 2026
DA - 2026/09/02
JO - NPJ vaccines
DO - 10.1038/s41541-026-01548-z
UR - https://europepmc.org/article/MED/42972001
AB - Seasonal influenza remains a leading cause of global morbidity and mortality, highlighting the need for vaccination strategies that improve coverage and streamline vaccine delivery. In this systematic review and meta-analysis, we searched PubMed, Embase, Web of Science, Scopus, and the Cochrane Central Register of Controlled Trials for randomised controlled trials (RCTs), cohort, case-control, and cross-sectional studies, evaluating immunogenicity and safety of same-day co-administration of influenza vaccines with COVID-19 or other vaccines, compared with non-concomitant administration. Comparators included sequential administration, single vaccine administration or placebo-controlled delayed vaccination. Risk of bias was evaluated using the Cochrane Risk-of-Bias tool for Randomized Trials and Risk of Bias In Non-randomized Studies of Interventions; certainty of evidence was evaluated using Grading of Recommendations, Assessment, Development and Evaluation. Immunogenicity was assessed using geometric mean fold rise (GMFR) in antibody titres and seroprotection rate. Safety was assessed by adverse event (AE) incidence. 52 eligible studies were included. Influenza immunogenicity was comparable between the co-administration and non-concomitant comparator group across all strains (H1N1 GMFR ratio of means (ROM): 1.02 [95% CI: 0.95-1.10]; H3N2, 1.05 [95% CI: 0.97-1.13]; B strain, 1.01 [95% CI: 0.97-1.05]). Pooled risk ratio (RR) for seroprotection was 1.00 for all three strains with 95% CIs ranging from 0.99-1.01. GMFR for COVID-19 vaccines was modestly reduced under co-administration (ROM 0.84 [95% CI: 0.74-0.95]; p = 0.006). Serious AEs were more frequent in the co-administration group compared to the non-concomitant group (RR 1.41 [95% CI: 1.07-1.86]; p = 0.014; absolute risk difference: 1.56 percentage points). Overall, co-administration preserves influenza immunogenicity but modestly reduces COVID-19 vaccine GMFR. Although safety findings warrant cautious interpretation, the low absolute risk difference supports its feasibility as a strategy to streamline vaccination schedules and improve uptake.
SN - 2059-0105
ER -